Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Higher serum 25(OH)D levels and age correlated with reduced relapse risk (p < 0.001 for both).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The data for this single center retrospective observational cohort study were collected via the Czech national multiple sclerosis registry (ReMuS) between January 2013 and December 2023.

Source: Methods.

Based on these 25(OH)D levels, patients were categorised into three groups:Group A: patients with an average 25(OH)D level below 75 nmol/L.Group B: patients with an average level between 75 nmol/L and 100 nmol/L.Group C: patients with an average level above 100 nmol/L.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

From sunlight to MS fight: impact of vitamin D levels on multiple sclerosis activity

Cohort study · Neurological Sciences · 2025

Original publication title

From sunlight to MS fight: impact of vitamin D levels on multiple sclerosis activity

Marta Vachova; Dominika Stastna; Aneta Mazouchova; Pavla Hruskova; Tomas Uher; Jana Preiningerova Lizrova; Pavel Potuznik; Jiri Drahota; Eva Kubala Havrdova

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our findings suggest that optimising 25(OH)D levels may reduce the risk of relapse in pwMS. Causation cannot be confirmed. Results highlight the importance of personalized vitamin D supplementation strategies and support the potential benefit of maintaining optimal serum 25(OH)D levels in MS management.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a multifactorial aetiology, including vitamin D levels, that have been linked to disease activity. Given the inconsistent findings on the vitamin D supplementation in MS, we aimed to analyse the connection between 25(OH)D levels and disease activity and to identify an optimal level of 25(OH)D in MS utilizing our real-world database.

Source: Background

Abstract: What methods does the paper describe?

This study utilized a 10-year dataset from the Czech national multiple sclerosis registry (ReMuS), encompassing 1,861 adult MS patients. Patients had a minimum of one year of follow-up, with subgroup analysis for those with at least five years. A mixed-effects model tested the impact of 25(OH)D and cholesterol levels on relapse incidence. Subgroup analysis categorised patients by average 25(OH)D levels and analysed relapse incidence using the Kruskal-Wallis test and Kaplan-Meier survival analysis.

Source: Methods

Abstract: Results

Higher serum 25(OH)D levels and age correlated with reduced relapse risk (p < 0.001 for both). Each 10 nmol/L increase in 25(OH)D levels associated with a 6.7% decrease in relapse risk (p < 0.001). Cholesterol levels and sex did not significantly affect relapse rate. Subgroup analysis revealed that patients with 25(OH)D levels above 100 nmol/L had significantly fewer relapses compared to those with levels below 75 nmol/L.

Source: Results

Abstract: Conclusion

Our findings suggest that optimising 25(OH)D levels may reduce the risk of relapse in pwMS. Causation cannot be confirmed. Results highlight the importance of personalized vitamin D supplementation strategies and support the potential benefit of maintaining optimal serum 25(OH)D levels in MS management.

Source: Conclusion
Authors’ abstract

Background

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a multifactorial aetiology, including vitamin D levels, that have been linked to disease activity. Given the inconsistent findings on the vitamin D supplementation in MS, we aimed to analyse the connection between 25(OH)D levels and disease activity and to identify an optimal level of 25(OH)D in MS utilizing our real-world database.

Methods

This study utilized a 10-year dataset from the Czech national multiple sclerosis registry (ReMuS), encompassing 1,861 adult MS patients. Patients had a minimum of one year of follow-up, with subgroup analysis for those with at least five years. A mixed-effects model tested the impact of 25(OH)D and cholesterol levels on relapse incidence. Subgroup analysis categorised patients by average 25(OH)D levels and analysed relapse incidence using the Kruskal-Wallis test and Kaplan-Meier survival analysis.

Results

Higher serum 25(OH)D levels and age correlated with reduced relapse risk (p < 0.001 for both). Each 10 nmol/L increase in 25(OH)D levels associated with a 6.7% decrease in relapse risk (p < 0.001). Cholesterol levels and sex did not significantly affect relapse rate. Subgroup analysis revealed that patients with 25(OH)D levels above 100 nmol/L had significantly fewer relapses compared to those with levels below 75 nmol/L.

Conclusion

Our findings suggest that optimising 25(OH)D levels may reduce the risk of relapse in pwMS. Causation cannot be confirmed. Results highlight the importance of personalized vitamin D supplementation strategies and support the potential benefit of maintaining optimal serum 25(OH)D levels in MS management.

Highlights

Optimising 25(OH)D levels may reduce multiple sclerosis relapse risk.

Each 10 nmol/L increase in 25(OH)D was linked to a 6.7% reduction in relapse risk.

Patients above 100 nmol/L of 25(OH)D had fewer relapses than those below 75 nmol/L.

No adverse effects were observed in the study.

Publication and source details

Original title: From sunlight to MS fight: impact of vitamin D levels on multiple sclerosis activity

Marta Vachova; Dominika Stastna; Aneta Mazouchova; Pavla Hruskova; Tomas Uher; Jana Preiningerova Lizrova; Pavel Potuznik; Jiri Drahota; Eva Kubala Havrdova

Neurological Sciences · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100003243Ministerstvo Zdravotnictví Ceské RepublikyMH CZ-DRO-VFN64165http://dx.doi.org/10.13039/501100009553Agentura Pro Zdravotnický Výzkum České RepublikyAZV NU22-04-00193

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:35:33.207127+00:00

DOI: 10.1007/s10072-025-08729-z · PMC12727803